I attended the Techknow Investor Roadshow and spoke to both Keating and Leedman at length around today’s announcement.
In a nutshell these results will comfortable allow us to submit and move forward with three critical diseases in the US. URTI, Lower Respiratory Tract infection along with a regulatory submission for asthma.
These three are the most commercially lucrative. Telehealth companies are after a quick differentiation between lower and upper respiratory tract infection which will determine whether or not a patient needs to see a doctor and go through standard testing. Remember ResApp is an aid to diagnosis!
To everyone’s main question: Why the discrepancy between Australians and US results?
A lot of the cases failed to reach a consensus between the adjudication panel (which is why the confidence intervals were low). Additionally the numbers were extremely small for pneumonia so a handful number of patients were able to swing the accuracy numbers considerably.
Keating mentioned he was able to explain each pneumonia adjudication decision case by case.
In the US, classifications of respiratory disease is heavily based around X-Rays and clinical procedures. In the Australian studies clinicians based their adjudication decisions around all available testing equipment (and are a lot more accurate imo).
Keating expects Croup results which will come out shortly to also be high enough for a submission as the subjectivity isn't determined by a multitude of tests in the US, its primarily by doctors.
Today's sell off was a complete market overreaction. The company is well funded, pursuing FDA submissions for numerous diseases along with TGA/CE clearance and will be revenue generating next year. Sleep Apnoea and monitoring of chronic diseases are also being pursued, there will be plenty of newsflow.
There will be heavy bounce in the coming sessions especially post the conference call tomorrow. Complete market overreaction for a product which will have FDA approval shortly.
P.S Nice to see everyone there
@Red bar @gothechooks @MrBenny @Rudy1 @minimogul and many others.
